ProQR's Q2 2026 Update: Cash Runway to Mid-2028 and a Pipeline of Clinical Milestones
PRQR sits 44% above its 52-week low of $1.33.
Summary
ProQR reported Q2 2026 financial results with a net loss of €8.7M and cash of €117.1M, supporting runway through mid-2028. Updates on the Axiomer RNA editing pipeline were also provided, including upcoming data readouts for AX-0810 and AX-0811.
Key Events · Earnings and Guidance · PRQR
-
Q2 2026 Financial Results
Net loss narrowed to €8.7M (€0.08/share) from €12.2M (€0.12/share) in Q2 2025, while revenue rose to €8.8M from €3.8M.
-
Cash Runway Extended
Cash and cash equivalents reached €117.1M as of June 30, 2026, up from €92.4M at year-end 2025, supporting runway through mid-2028.
-
AX-0811 CTA Submitted
A Clinical Trial Application was submitted to the EMA in July 2026 for a Phase 1 trial of AX-0811, a next-generation NTCP-targeting EON.
-
Upcoming Clinical Milestones
AX-0810 full Phase 1 data by year-end 2026; AX-0811 initial data by year-end 2026; biliary atresia IIT initiation and initial data in H1 2027; AX-0422 initial data in H1 2027; AX-2911 FIH IIT in H1 2027.
Analysis · PRQR · Life Sciences
The second quarter of 2026 brought a narrower net loss and a stronger cash position of €117.1M, extending the runway to mid-2028. A detailed pipeline update accompanied the results, including the CTA submission for AX-0811 and multiple data readouts expected over the next 18 months. For investors tracking clinical progress and financial stability, this is a meaningful update.
At the time of this filing, PRQR was trading at $1.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $256.8M. The 52-week trading range was $1.33 to $3.10. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.